Abstract
A 50-mg dose containing 50 µCi 14C-isomazole was administered orally to five healthy male volunteers. Blood, plasma, urine, feces, and saliva were collected and measured for total 14C; in addition, all collections except feces were measured for parent drug (ISO) and three metabolites: hydroxyisomazole (OHISO) and sulfone (SULF) and hydroxysulfone (OHSULF) analogues. Urine and fecal recoveries accounted for 97.0% of the drug administered, with 62.6% excreted in urine and 32.4% in feces. Only 47% of the drug recovered in urine could be identified, with ISO the largest constituent. Total plasma 14C peaked at 1.5 hr, indicating rapid absorption, and produced a mean half-life of 3.7 hr. This was similar to the total 14C half-life found in blood (3.1 hr) but longer than in red blood cells (1.8 hr) or saliva (1.4 hr), suggesting that different ISO-related compounds contributed to the results found in each fluid or tissue. An unidentified metabolite(s) composed a large portion of circulating plasma 14C and produced the longer half-life encountered in plasma. ISO exhibited a short half-life (1.35 hr), a high oral clearance (ClS/F; 24.2 ml/min/kg), and some extravascular distribution (Vβ; 3.07 L/kg). Total 14C in red blood cells and saliva related very well to plasma ISO disposition, suggesting preferential distribution of parent drug across cellular membranes. The estimated RBC:plasma ISO ratio (1.79) confirmed this hypothesis. Saliva may be used as a noninvasive means to monitor ISO disposition.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
P. J. Cannon. A placebo controlled trial of captopril in refractory chronic congestive heart failure. J. Am. Coll. Cardiol. 2:755–763 (1983).
R. R. Miller, A. R. Palomo, B. S. Brandon, C. J. Hartley, and M. A. Quinones. Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts. Am. Heart J. 102:500–508 (1981).
J. Cohn. Effect of vasodilator therapy on mortality in congestive heart failure. N. Engl. J. Med. 314:1547–1552 (1986).
J. S. Hayes, J. Bowling, G. D. Pollack, and D. W. Robertson. Roles for Ca++ and cyclic AMP in mediating the cardiotonic actions of isomazole (LY175326). J. Pharmacol. Exp. Ther. 237:18–24 (1986).
J. S. Hayes, G. D. Pollock, H. Wilson, N. Bowling, and D. W. Robertson. Pharmacology of LY175326: A potent cardiotonic agent with vasodilator activities. J. Pharmacol. Exp. Ther. 233:318–326 (1985).
J. R. Means, R. B. Franklin, and G. E. Sandusky. Toxicological evaluation of the cardiotonic isomazole in the dog. Fund. Appl. Toxicol. 13:418–428 (1989).
G. E. Sandusky, R. B. Franklin, and J. R. Means. Acute, sub-chronic, and chronic toxicity of the cardiotonic isomazole in rats. Fund. Appl. Toxicol. 13:409–417 (1989).
J. R. Bernstein and R. B. Franklin. In vivo reduction and reoxidation of isomazole: studies with 18O-labelled isomazole. Med. Sci. Res. 15:569–570 (1987).
J. R. Woodworth, A. F. DeLong, A. F. Fasola, and S. Oldham. Isomazole disposition as a function of dose and route of administration (accepted for publication Biopharm. Drug Dispos.).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Woodworth, J.R., DeLong, A.F., Fasola, A. et al. 14C-Isomazole Disposition in Man After Oral Administration. Pharm Res 8, 1413–1417 (1991). https://doi.org/10.1023/A:1015857324838
Issue Date:
DOI: https://doi.org/10.1023/A:1015857324838